Published in:
Open Access
01-12-2012 | Research
Safety and feasibility of countering neurological impairment by intravenous administration of autologous cord blood in cerebral palsy
Authors:
Young-Ho Lee, Kyung Vin Choi, Jin Hwa Moon, Hyun-Joo Jun, Hye-Ryeong Kang, Se-In Oh, Hyung Sun Kim, Jang Soo Um, Mi Jung Kim, Yun Young Choi, Young-Jun Lee, Hee-Jin Kim, Jong-Hwa Lee, Su Min Son, Soo-Jin Choi, Wonil Oh, Yoon-Sun Yang
Published in:
Journal of Translational Medicine
|
Issue 1/2012
Login to get access
Abstract
Backgrounds
We conducted a pilot study of the infusion of intravenous autologous cord blood (CB) in children with cerebral palsy (CP) to assess the safety and feasibility of the procedure as well as its potential efficacy in countering neurological impairment.
Methods
Patients diagnosed with CP were enrolled in this study if their parents had elected to bank their CB at birth. Cryopreserved CB units were thawed and infused intravenously over 10~20 minutes. We assessed potential efficacy over 6 months by brain magnetic resonance imaging (MRI)-diffusion tensor imaging (DTI), brain perfusion single-photon emission computed tomography (SPECT), and various evaluation tools for motor and cognitive functions.
Results
Twenty patients received autologous CB infusion and were evaluated. The types of CP were as follows: 11 quadriplegics, 6 hemiplegics, and 3 diplegics. Infusion was generally well-tolerated, although 5 patients experienced temporary nausea, hemoglobinuria, or urticaria during intravenous infusion. Diverse neurological domains improved in 5 patients (25%) as assessed with developmental evaluation tools as well as by fractional anisotropy values in brain MRI-DTI. The neurologic improvement occurred significantly in patients with diplegia or hemiplegia rather than quadriplegia.
Conclusions
Autologous CB infusion is safe and feasible, and has yielded potential benefits in children with CP.